by Mark Curtis | Mar 24, 2016
Welcome to your Update from the Clinic for the month of February. bluebird made its debut in the oncology market and treated its first patient with a chimeric antigen receptor (CAR) product targeting a novel antigen. Ziopharm enrolled its first patient in a study...
by Stacey Johnson | Mar 18, 2016
We don’t need no education We don’t need no thought control No dark sarcasm in the classroom Teachers leave them kids alone Hey! teachers! leave the kids alone! All in all it’s just another brick in the wall. All in all you’re just another...
by Mark Curtis | Mar 15, 2016
Welcome to your deal review for the month of February. Astellas tied-off its acquisition of Ocata while GSK and Adaptimmune expanded their collaboration to develop cell-based immunotherapies. AVROBIO, a new cell and gene company based in Boston, Mass, and Toronto,...
by Stacey Johnson | Mar 11, 2016
Tissue engineering is a key part of regenerative medicine (RM), but it sometimes feels like the poor cousin of stem cells. The Jan to big sister Marcia. That won’t be the case at the upcoming 10th World Biomaterials Congress (WBC2016), happening May 17-22 in Montreal,...
by James Smith | Mar 7, 2016
Post by James Smith and Mackenna Roberts. Ms. Roberts is an English-qualified lawyer, trained bioethicist and strategic adviser for the commercialization of emerging biomedical technologies and is widely published on how the law should govern cutting-edge medical...
by Stacey Johnson | Mar 4, 2016
Last week, I wrote about Dr. Leon Bellan’s creative solution to engineering artificial blood vessels for lab-grown organs: cotton candy! As much as I was impressed with his out-of-the-box thinking, I also really liked the excellent video produced by Vanderbilt...
by Nicole Kuchinsky | Feb 29, 2016
Japan is making bold moves to redefine how cell therapies make it to market, and the world is taking notice. In late January, the Japan External Trade Organization (JETRO) collaborated with the Centre for Commercialization of Regenerative Medicine (CCRM) to host a...
by Stacey Johnson | Feb 26, 2016
Whether you call it cotton candy, candy floss or the original name for it “fairy floss,” I’m going to assume you’ve never called it “a tool for creating artificial blood vessels.” (Too long and not very appetizing.) Nevertheless, Dr. Leon Bellan, Vanderbilt...
by Mark Curtis | Feb 22, 2016
Welcome to your update from the clinic for the month of January. It was a quiet month in the clinic. However, we did see some clearances for various clinical studies, including Fate’s ProTmune in GvHD and Pluristem’s PLX-R18 in hematopoietic recovery following bone...
by Stacey Johnson | Feb 19, 2016
I had the pleasure of talking about my career to my daughter’s class when she was in grade 5. In an effort to keep the kids awake, I avoided a potentially sleep-inducing talk about corporate communications and instead focused most of my presentation on giving a simple...
Comments